Pharmaceutical

Enara Bio secures $32.5m for ‘Dark Antigen’ cancer therapies

Pfizer and Merck KGaA’s venture capital arms were among the backers in the Series B round.

Oct 4, 2024 - 04:00
Enara Bio secures $32.5m for ‘Dark Antigen’ cancer therapies
Pfizer and Merck KGaA’s venture capital arms were among the backers in the Series B round.
Read the original article

Tags:

Previous Article

Chronic diseases “as urgent as climate change,” says Novo Nordisk CSO

Next Article

Healthcare Payers for the Pharmaceutical Industry

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: How small vaccine stockpiles can stop outbreaks of infectious disease from becoming big

Opinion: How small vaccine stockpiles can stop outbreak...

Apr 25, 2023

Listen: A CRISPR milestone, algorithms amok, & biotech mixology

Listen: A CRISPR milestone, algorithms amok, & biotech ...

Nov 17, 2023

What’s behind the urge to scratch that itch? Harvard researchers have a theory

What’s behind the urge to scratch that itch? Harvard re...

Nov 23, 2023